Impact Biomedical (IBO) Intangibles (2022 - 2026)
Impact Biomedical's (IBO) quarterly Intangibles came in at $22.6 million in Q1 2026, up 26.51% YoY from $17.9 million in Q1 2025, and up 32.9% on a QoQ basis from $17.0 million in Q4 2025.
Impact Biomedical (IBO) Intangibles (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Intangibles data on file, last reported at $22.6 million in Q1 2026.
- Quarterly Intangibles rose 26.51% year-over-year to $22.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.6 million (up 26.51% YoY) and the FY2025 annual result came in at $17.0 million, down 23.66% from the prior year.
- Intangibles improved to $22.6 million in Q1 2026, from $17.0 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $22.6 million in Q1 2026 to a low of $17.0 million in Q4 2025.
- A 5-year average of $19.3 million and a median of $18.6 million in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2025 — Intangibles dropped 23.66% — and 2026, when it gained 26.51%.
- Tracing IBO's Intangibles over 5 years: stood at $20.0 million in 2022, then dropped by 5.56% to $18.9 million in 2023, then increased by 17.65% to $22.3 million in 2024, then retreated by 23.66% to $17.0 million in 2025, then surged by 32.9% to $22.6 million in 2026.
- The last three Intangibles figures came in at $22.6 million (Q1 2026), $17.0 million (Q4 2025), and $17.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 22.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.59 Mn |
| Mar 31, 2026 | 22.59 Mn |
| Dec 31, 2025 | 16.99 Mn |
| Sep 30, 2025 | 17.28 Mn |
| Jun 30, 2025 | 17.57 Mn |
| Mar 31, 2025 | 17.85 Mn |
| Dec 31, 2024 | 22.26 Mn |
| Sep 30, 2024 | 18.09 Mn |
| Jun 30, 2024 | 18.37 Mn |
| Mar 31, 2024 | 18.64 Mn |
| Dec 31, 2023 | 18.92 Mn |
| Sep 30, 2023 | 22.26 Mn |
| Jun 30, 2023 | 19.48 Mn |
| Dec 31, 2022 | 20.03 Mn |